David H. Johnson

发表

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer

J. Minna, J. Roth, I. Wistuba, 2018, Clinical Cancer Research.

An Analysis of Individual Body Fat Depots and Risk of Developing Cancer: INSIGHTS FROM THE DALLAS HEART STUDY

C. Ayers, S. Grundy, G. Vega, 2017, Mayo Clinic proceedings.

Plasma Leptin Levels and Risk of Incident Cancer: Results from the Dallas Heart Study

C. Ayers, David H. Johnson, Arjun Gupta, 2016, PloS one.

Rules for recruiting.

David H. Johnson, David H Johnson, 2014, Journal of oncology practice.

The American Board of Internal Medicine: Evolving Professional Self-regulation

David H. Johnson, R. Baron, David H Johnson, 2014, Annals of Internal Medicine.

Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity

Xian-Jin Xie, S. Ramalingam, D. Gerber, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Applying the 'COST' (Culture, Oversight, Systems Change, and Training) Framework to De-Adopt the Neutropenic Diet.

David H. Johnson, Shruti Singh, Arjun Gupta, 2019, The American journal of medicine.

Reply to A. Braillon.

P. Bunn, J. Schiller, David H. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer

J. Minna, J. Roth, I. Wistuba, 2017, Clinical Cancer Research.

Recent clinical advances in lung cancer management.

P. Bunn, J. Schiller, David H. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital.

David H. Johnson, Arjun Gupta, T. Brown, 2019, Journal of oncology practice.

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug shortage leading to serendipitous adoption of high-value care practice

David H. Johnson, D. Agrawal, David H Johnson, 2017, BMJ Quality & Safety.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Financial disclosure, industry sponsorship, and integrity in cancer research reporting.

David H. Johnson, David H Johnson, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiphospholipid Antibodies

David H. Johnson, S. Nagalla, Arjun Gupta, 2017, JAMA.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599

R. Gray, J. Schiller, David H. Johnson, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

J. Pignon, N. Saijo, M. Fukuoka, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go?

David H. Johnson, David H Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

W. McCaskill-Stevens, S. Lippman, F. Khuri, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer

David H. Johnson, Lisa I. Wang, J. Yi, 2010, Journal of Thoracic Oncology.

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.

J. Schiller, David H. Johnson, S. Dahlberg, 2013, Lung cancer.

Things We Do For No Reason: Neutropenic Diet

David H. Johnson, Arjun Gupta, N. Sadeghi, 2018, Journal of hospital medicine.

A Career in Lung Cancer: Pushing Beyond Chemotherapy.

F. Shepherd, David H. Johnson, P. Patil, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Pemberton’s sign in SVC syndrome from metastatic renal cell carcinoma

David H. Johnson, N. Keshvani, C. Yek, 2018, BMJ Case Reports.

Near-complete vision recovery from bilateral serous retinal detachment associated with thrombotic thrombocytopenic purpura

David H. Johnson, Saikripa M Radhakrishnan, David H Johnson, 2022, BMJ Case Reports.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer

J. Yi, J. Schiller, David H. Johnson, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis.

David H. Johnson, Arjun Gupta, D. Pardi, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer

D. Carbone, Y. Shyr, David H. Johnson, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Staging CT Scans in Early-Stage Chronic Lymphocytic Leukemia.

David H. Johnson, Arjun Gupta, S. Choi, 2017, JAMA internal medicine.

Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer

Guanghua Xiao, Tao Wang, Yang Xie, 2019, Cancer informatics.

The Department of Medicine in 2030: A Look Ahead.

David H. Johnson, David L Coleman, 2016, American Journal of Medicine.

Rules for recruiting.

David H. Johnson, 2014, Journal of Oncology Practice.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

J. Schiller, David H. Johnson, A. Sandler, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.